According to Technavio’s latest market research study, the global bipolar disorder therapeutic market is expected to grow at a CAGR of more than 2% during the forecast period, 2017-2021.
This report by Technavio provides an in-depth analysis of the global bipolar disorder therapeutic market in terms of revenue and emerging market trends. The report also includes an up-to-date analysis and forecasts for various market segments and all geographical regions.
Technavio research analysts categorize the market based on the drug class type
Click here to request a free sample of this report
The top three revenue contributing drug class segments are discussed below:
Global antipsychotics market: Antipsychotics are mainly used to manage psychotic symptoms and are often used in conjunction with mood stabilizers to treat bipolar disorder. According to the industry analysts at Technavio, the market’s growth during the forecast period will be driven by factors such as high dependency on antipsychotic drugs in the treatment of bipolar disorder, large investments in the R&D of this drug class by market leaders, and the entry of new drugs.
“Traditionally, typical antipsychotics were the preferred treatment for psychotic and agitation treatment for mania. However, atypical or second-generation antipsychotics are becoming increasingly popular owing to fewer extrapyramidal side-effects such as paranoia, tremors, anxiety, or dystonia,” says Barath Palada, a lead analyst at Technavio for research on central nervous system.
Global anticonvulsants market: Anticonvulsants are used extensively to control mania. The market for anticonvulsants is projected to experience substantial growth during the forecast period owing to extensive application of anticonvulsants for the treatment of bipolar disorder, both alone and in combination with other medications. The common anticonvulsants used for manic episodes include valproic acid/divalproex or carbamazepine.
Global traditional mood stabilizers market: Often termed as a traditional mood stabilizer, lithium is the oldest and least expensive drug for bipolar disorder. The extensive use of lithium as a first-line treatment for bipolar disorder is expected to maintain the growth rate of the market. The effectiveness of lithium in reducing chances of suicide is one of the major drivers of the market for traditional mood stabilizers such as lithium.
The top vendors operating in the global bipolar disorder therapeutics market are:
- Eli Lilly
- Bristol-Myers Squibb
- AstraZeneca
Other prominent vendors in the market include Allergan, Astellas Pharma, GlaxoSmithKline, and Janssen Pharmaceuticals.
A more detailed analysis is available in the Technavio report titled, ‘Global Bipolar Disorder Therapeutic Market 2017-2021’. Technavio also customizes reports by other regions and specific segments upon request.
Other related reports:
- Global Protein Therapeutics Market 2017-2021
- Global Chemotherapy-induced Nausea and Vomiting Drugs Market 2017-2021
- Global Pompe Disease Treatment Market 2016-2020
To read more press releases – click here
